Anti-shock toxin antibody drug for combat casualty care

Ended Purchase Order Awarded Last action

Contract number
FA864924P0719
Awardee
Awarding agency
Obligated
$72,672

Award facts

Contract value 100% obligated
$72,672.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
Total Small Business
Competition
Full and Open Competition after exclusion of sources Negotiated Proposal / Quote
Pricing
Firm Fixed Price
Place of performance
Arlington, MD 21215, USA
Research
SBIR Program Phase I Action

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Supplemental Agreement for work within scope P00001 $0
Original award $72,672

About this award

The U.S. Air Force Research Laboratory (AFRL) awarded a $72,672.00 Small Business Innovation Research (SBIR) Program Phase I firm-fixed-price purchase order to NKA Bio, Inc. for the development of an anti-shock toxin antibody drug for combat casualty care. The contract has a completion date of December 17, 2024. As a small disadvantaged business, NKA Bio, Inc. was awarded this SBIR Phase I contract to perform research and development related to the delivery of a medical countermeasure for combat operations.

Quick answers

Who was awarded contract FA864924P0719?

FA864924P0719 was awarded to NKA Bio, Inc. by Air Force Research Laboratory (Air Force Materiel Command) on September 17, 2024.

How much is contract FA864924P0719 worth?

The government has obligated $72,672 on FA864924P0719.

Was contract FA864924P0719 competed?

The extent of competition for FA864924P0719 was full and open competition after exclusion of sources. It was set aside: Total Small Business.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award